Emerging cannabinoids differ in behavioral safety margins in mice: a comparative hazard proximity analysis of locomotor suppression and catalepsy-like immobility.
Shintaro Shirakura, Arisa Ohta, Hiroko Abe, Kayo Nakamura, Akihiko Ishida, Manabu Tokeshi, Kyohei Higashi, Hideyo Takahashi, Akiyoshi Saitoh
Forensic Toxicology September 14, 2026 DOI: 10.1007/s11419-026-00786-z (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Animal study Peer reviewed |
|---|---|
| Population | Male C57BL/6J mice |
| Interventions | Δ9-tetrahydrocannabinol (THC) hexahydrocannabinol (HHC) tetrahydrocannabihexol (THCH) tetrahydrocannabivarin (THCV) hexahydrocannabihexol (HHCH) hexahydrocannabiphorol (HHCP) |
| Measures | bar test, spontaneous locomotor activity, ED50, Hazard Proximity Index (HPI) |
| Key points | All six cannabinoids reduced spontaneous locomotor activity, but catalepsy-like immobility varied: THC, THCH, HHCH, and HHCP produced robust immobility, HHC induced only weak, non-significant immobility, and THCV increased immobility only at higher doses without reaching 50% catalepsy. The authors report that psychomotor suppression occurred at lower doses than catalepsy-like toxicity and propose the Hazard Proximity Index (HPI) as a screening metric; HPI values were 25.6% for THC, 45.1% for THCH, 5.1% for HHC, 33.2% for HHCH, and 3.7% for HHCP. |
Abstract
Purpose: Novel cannabinoids, including tetrahydrocannabihexol (THCH), tetrahydrocannabivarin (THCV), hexahydrocannabinol (HHC), hexahydrocannabihexol (HHCH), and hexahydrocannabiphorol (HHCP), have raised toxicological concerns, but their acute neurobehavioral effects remain poorly understood. This study compared the in vivo potencies of six cannabinoids using locomotor suppression and catalepsy-like immobility as indices of psychomotor suppression and toxic motor impairment, respectively.
Methods: Male C57BL/6J mice received intraperitoneal administration of Δ9-tetrahydrocannabinol (THC), HHC, THCH, THCV, HHCH, or HHCP. Catalepsy-like immobility was assessed using the bar test 20 min after dosing (maximum latency, 300 s), and spontaneous locomotor activity was recorded for 10 min beginning 35 min after dosing. ED50 values were determined for locomotor suppression and catalepsy-like immobility, and the Hazard Proximity Index (HPI, %) was calculated as (ED50_locomotor / ED50_catalepsy) × 100, with higher values indicating a narrower behavioral safety margin.
Results: All cannabinoids reduced spontaneous locomotor activity. THC, THCH, HHCH, and HHCP produced robust catalepsy-like immobility, whereas HHC induced only weak, non-significant immobility. THCV increased immobility only at higher doses and did not reach 50% catalepsy within the tested dose range. HPI values were 25.6% for THC, 45.1% for THCH, 5.1% for HHC, 33.2% for HHCH, and 3.7% for HHCP; HPI was not calculated for THCV.
Conclusions: Psychomotor suppression occurred at lower doses than catalepsy-like toxicity. Some side-chain-extended cannabinoids, particularly THCH and HHCH, showed a narrower separation between these endpoints. These findings provide comparative ED50 benchmarks and introduce the HPI as a novel ED50-based screening metric for the relative prioritization of emerging cannabinoids in forensic toxicology.
Citations in the library
Cites 11
- Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment Journal of Psychopharmacology October 5, 2012
- Hexahydrocannabinol: pharmacokinetics, systemic toxicity, and acute behavioral effects in Wistar rats. The International Journal of Neuropsychopharmacology August 1, 2025
- Cannabimimetic and discriminative stimulus effects of hexahydrocannabinols in mice. Journal of Psychopharmacology July 1, 2025
- In vitro activation of the CB1 receptor by the semi‐synthetic cannabinoids hexahydrocannabinol (HHC), hexahydrocannabinol acetate (HHC‐O) and hexahydrocannabiphorol (HHC‐P) Drug Testing and Analysis June 19, 2024
- The dose-dependent psychomotor effects of intravenous delta-9-tetrahydrocannabinol (Δ9-THC) in humans. Journal of Psychopharmacology December 2018
and 6 more in the library